Intuitive Surgical (ISRG) Peer Comparison
$443.82
As on 02-Nov-2026 13:38EST
Market cap
$152,620 Mln
Revenue (TTM)
$11,578 Mln
P/E Ratio
54.3
P/B Ratio
9.9
Div. Yield
0 %
| Intuitive Surgical (ISRG) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Stryker (SYK) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
152,620 | 262,217 | 180,946 | 166,594 | 119,579 |
Revenue ($ Mln) |
11,578 | 47,351 | 48,229 | 25,608 | 26,300 |
Net Profit ($ Mln) |
2,957.20 | 7,083.00 | 4,701.00 | 4,331.00 | 3,623.00 |
Net Margin (%) |
25.54 | 14.96 | 9.75 | 16.91 | 13.78 |
RoE (%) |
17.58 | 13.25 | 18.06 | 8.13 | 15.60 |
Price to Earnings |
54.27 | 37.40 | 38.87 | 39.24 | 32.31 |
Price-To-Book |
9.92 | 4.75 | 3.48 | 3.07 | 4.86 |
Income Statement ($ Mln)
| Intuitive Surgical (ISRG) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
11,578.00 | 47,351.00 | 48,229.00 | 25,608.00 | 26,300.00 |
|
Cost of Revenue
|
3,798.50 | 27,729.00 | 20,681.00 | 10,603.00 | 9,067.00 |
|
Gross Profit
|
6,642.30 | 18,239.00 | 24,607.00 | 14,970.00 | 16,065.00 |
|
Operating Expenses
|
4,495.40 | 11,106.00 | 20,197.00 | 9,787.00 | 11,643.00 |
|
Operating Profit (EBIT)
|
3,284.10 | 8,515.00 | 7,351.00 | 5,218.00 | 5,590.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
3,619.00 | 7,869.00 | 6,562.00 | 4,818.00 | 5,116.00 |
|
Provision for Tax
|
645.90 | 742.00 | 1,861.00 | 487.00 | 1,493.00 |
|
Profit after Tax (Net Income)
|
2,957.20 | 7,083.00 | 4,701.00 | 4,331.00 | 3,623.00 |
|
Minority Interest
|
-15.90 | -16.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 1,964.00 | 1,776.00 | 1,197.00 | 849.00 |
Liabilities ($ Mln)
| Intuitive Surgical (ISRG) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
15,986.20 | 54,767.00 | 0.00 | 53,621.00 | 23,457.00 |
|
Minority Interest
|
-15.90 | -16.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
698.30 | 45,296.00 | 0.00 | 30,610.00 | 17,290.00 |
|
Current Liabilities
|
2,533.00 | 14,170.00 | 0.00 | 9,050.00 | 6,500.00 |
|
Total Liabilities
|
20,631.20 | 110,343.00 | 86,713.00 | 83,464.00 | 47,844.00 |
Assets ($ Mln)
| Intuitive Surgical (ISRG) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
10,920.80 | 88,618.00 | 0.00 | 78,494.00 | 33,064.00 |
|
Current Assets
|
8,428.30 | 25,615.00 | 0.00 | 14,787.00 | 14,183.00 |
|
Total Assets
|
20,631.20 | 110,343.00 | 86,713.00 | 83,464.00 | 47,844.00 |
|
Total Debt*
|
0.00 | 41,370.00 | 0.00 | 26,482.00 | 14,176.00 |
|
Net Current Assets
|
5,895.30 | 0.00 | 0.00 | 5,737.00 | 0.00 |
Cashflow ($ Mln)
| Intuitive Surgical (ISRG) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
3,030.50 | 7,818.00 | 9,566.00 | 6,416.00 | 5,044.00 |
|
Cash Flow from Investing Activities
|
665.80 | -4,047.00 | -2,422.00 | -1,196.00 | -4,866.00 |
|
Cash from Financing Activities
|
-2,364.10 | 1,801.00 | -6,309.00 | -2,961.00 | 113.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Intuitive Surgical (ISRG) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
16.46 | 7.69 | 10.03 | 5.25 | 8.83 |
|
ROE (%)
|
17.58 | 13.25 | 18.06 | 8.13 | 15.60 |
|
ROA (%)
|
13.74 | 5.50 | 9.52 | 4.59 | 6.25 |
|
EBIT Margin (%)
|
33.80 | 13.63 | 11.82 | 20.22 | 20.59 |
|
Net Margin (%)
|
25.54 | 14.96 | 9.75 | 16.91 | 13.78 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Intuitive Surgical (ISRG) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
20.45 | 8.27 | 10.00 | 5.52 | 7.87 |
|
EBIT Growth (%)
|
23.61 | -24.37 | -34.24 | 16.46 | 48.61 |
|
Net Profit Growth (%)
|
7.66 | 7.81 | -66.37 | 23.64 | 23.11 |
|
EPS Growth (%)
|
9.30 | 9.68 | -66.31 | 26.16 | 23.26 |
|
Book Value Growth (%)
|
-2.83 | 9.37 | -- | 6.02 | 8.23 |
Valuation Ratios
| Intuitive Surgical (ISRG) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
71.47 | 32.43 | 33.55 | 45.04 | 41.85 |
|
Price / Book Value
|
11.45 | 4.09 | 4.20 | 3.10 | 6.06 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
49.76 | 21.61 | 18.87 | 25.42 | 23.46 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Intuitive Surgical (ISRG) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.29 | 0.45 | 0.00 |
|
Short term debt to equity ratio
|
0.00 | 0.04 | 0.06 | 0.04 | 0.03 |
|
Current Ratio
|
3.33 | 1.81 | 1.58 | 1.63 | 2.18 |
|
Quick Ratio
|
2.49 | 1.41 | 1.18 | 1.29 | 1.30 |
|
Interest Coverage
|
-- | 6.12 | 8.37 | 14.38 | 8.64 |
Operating Efficiency Ratios
| Intuitive Surgical (ISRG) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Stryker (SYK) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
14.87 | 20.33 | 0.00 | 20.02 | 14.04 |
|
Asset Turnover
|
0.54 | 0.37 | 0.98 | 0.27 | 0.45 |
|
Receivable days
|
54.16 | 82.76 | 61.20 | 61.72 | 58.36 |
|
Inventory Days
|
177.54 | 72.19 | 117.44 | 91.69 | 203.47 |
|
Payable days
|
23.93 | 46.50 | 78.11 | 68.44 | 70.18 |
|
Cash Conversion Cycle
|
207.78 | 108.45 | 100.53 | 84.97 | 191.65 |